Supplementary table: Summary of AEs (ITT population)

AEs, n (%)	Pre-belimumab cohort N=34	Belimumab-concurrent cohort N=45
Any AE[a]	31 (91.2)	39 (86.7)
Arthralgia	6 (17.6)	10 (22.2)
Nausea	6 (17.6)	9 (20.0)
Viral gastroenteritis	1 (2.9)	6 (13.3)
Cough	4 (11.8)	3 (6.7)
Dizziness	4 (11.8)	2 (4.4)
Diarrhea	3 (8.8)	5 (11.1)
Treatment-related AE	8 (23.5)	4 (8.9)
Vaccine-related AE	0	2 (4.4)
Any SAE	4 (11.8)	3 (6.7)
Severe AE	8 (23.5)	9 (20.0)
Serious and/or severe AE	9 (26.5)	10 (22.2)
AE resulting in study agent discontinuation	3 (8.8)	0
Death	0	0

[a]AEs reported in ≥10% of patients in either cohort are listed.
AE, adverse event; ITT, intent-to-treat; SAE, serious adverse event.